Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor).

  title={Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor).},
  author={T. Nakada and T. Kazama and H. Koike and M. Yoshikawa and S. Ishikawa and T. Katayama},
  volume={25 2},
  • T. Nakada, T. Kazama, +3 authors T. Katayama
  • Published 1985
  • Medicine
  • Urology
  • The practicability and tolerability of trilostane, a competitive inhibitor of 3 beta-hydroxysteroid-delta 5-dehydrogenase, for the therapy of primary aldosteronism was assessed in 1 patient with aldosterone-producing adenoma (APA) and 3 subjects with idiopathic adrenal hyperplasia (IHA). Trilostane afforded reduction of plasma levels of aldosterone, progesterone, deoxycorticosterone, 17-OH progesterone, cortisol, delta 4-androstenedione, and urinary excretion of 17-hydroxycorticosteroid… CONTINUE READING
    14 Citations
    Therapeutic results of primary aldosteronism with special reference to renal or renovascular lesions
    • 5
    Heterosteroids and drug research.
    • 41
    Trilostane in advanced breast cancer
    • 10


    Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
    • 109
    Triamterene‐thiazide combination: Alternative therapy for primary aldosteronism
    • 28
    Amiloride in primary hyperaldosteronism
    • 40
    The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma.
    • 793
    • PDF
    Disposition of trilostane in the rat and monkey.
    • 11
    Study of the Norymberski methods for determination of 17-ketogenic steroids (17-hydroxycorticosteroids) in urine.
    • 88
    Gynecomastia induced in normal males by spironolactone
    • 34